Rembrandt Diagnostics, LP v. Alere, Inc., No. 19-1595 (Fed. Cir. Apr. 10, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

These appeals arise from an action for patent infringe- ment. Rembrandt Diagnostics, LP sued Alere, Inc., Alere Toxicology Services, Inc., Innovacon, Inc., and Instant Technologies, Inc. (collectively, “Alere”), alleging that Alere’s products infringe claims 3–6 and 10 of Rembrandt’s U.S. Patent No. 6,548,019, directed to devices for collecting and assaying biological fluid samples. Prior to trial, Rem- brandt stipulated to a judgment of noninfringement of claims 3–6 in light of the district court ’s construction of a disputed claim limitation.